ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
Roche 's RHHBY Rituxan (rituximab) and Bristol Myers ' BMY Revlimid (lenalidomide) (R ), to treat indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The early to mid-stage study is sponsored and conducted by MD Anderson Cancer Center, which is based in Texas. ALX Oncology announced that, per findings, patients receiving evorpacept in combination with standard R treatment achieved a promising initial activity with a best overall response rate (ORR) of 94% and a complete response rate (CRR) of 83% in patients with indolent R/R B-NHL. The results are even better than that observed with only R treatment, reporting an ORR of 78% and a CRR of 34% in the benchmark phase III AUGMENT clinical study, which was conducted in a similar patient population. ALX Oncology reported that the phase I/II study enrolled 20 R/R B-NHL patients (18 indolent and 2 aggressive) who had previously been treated with Roche's Rituxan. Out of the total patient population, 72
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerGlobeNewswire
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingGlobeNewswire
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
ALXO
Earnings
- 11/13/23 - Miss
ALXO
Sec Filings
- 4/23/24 - Form ARS
- 4/22/24 - Form DEF
- 4/18/24 - Form 4
- ALXO's page on the SEC website